News Releases :: Sutro Biopharma, Inc. (STRO)

May 14, 2020 4:01 pm EDT

Sutro Biopharma Announces Closing of $98.0 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

May 11, 2020 11:55 pm EDT

Sutro Biopharma Announces Pricing of $85.3 Million Public Offering

May 11, 2020 4:15 pm EDT

Sutro Biopharma Reports First Quarter 2020 Financial Results and Recent Business Highlights and Developments

May 11, 2020 4:01 pm EDT

Sutro Biopharma Announces Proposed Public Offering

Apr 27, 2020 12:01 am EDT

Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer

Apr 20, 2020 4:35 pm EDT

Sutro Biopharma to Host Conference Call on April 27, 2020, to Provide Clinical Update on its STRO-002 Antibody-Drug Conjugate

Apr 13, 2020 5:00 pm EDT

Sutro Biopharma to Present Updated Clinical Data for its STRO-002 Antibody-Drug Conjugate at the AACR Virtual Annual Meeting on April 27, 2020

Mar 16, 2020 7:00 am EDT

Sutro Biopharma Reports Full Year 2019 Financial Results and Recent Business Highlights and Developments

Mar 12, 2020 7:00 am EDT

Sutro Biopharma Announces Extension of First Cytokine Derivative Research Program Under Collaboration with Merck

Mar 4, 2020 7:00 am EST

Sutro Biopharma to Present Innovative Cancer Therapy Approach Using Precise Tumor Targeted Immunostimulants at World ADC London